Media headlines about Catabasis Pharmaceuticals (NASDAQ:CATB) have trended somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Catabasis Pharmaceuticals earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 47.0633564668997 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

CATB has been the topic of several recent research reports. HC Wainwright boosted their price objective on shares of Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Monday, August 14th. Oppenheimer Holdings, Inc. decreased their price objective on shares of Catabasis Pharmaceuticals from $9.00 to $4.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 15th. Citigroup Inc. reiterated a “hold” rating and issued a $1.50 price objective on shares of Catabasis Pharmaceuticals in a research report on Friday, September 29th. CIBC restated an “outperform” rating and issued a $7.00 target price (up from $4.00) on shares of Catabasis Pharmaceuticals in a report on Thursday, October 5th. Finally, Cowen and Company restated a “market perform” rating and issued a $2.00 target price on shares of Catabasis Pharmaceuticals in a report on Friday, October 6th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $4.82.

Catabasis Pharmaceuticals (NASDAQ:CATB) traded down $0.03 during trading hours on Monday, reaching $1.62. 191,400 shares of the company’s stock were exchanged, compared to its average volume of 1,066,469. Catabasis Pharmaceuticals has a 52 week low of $1.08 and a 52 week high of $5.51.

Catabasis Pharmaceuticals (NASDAQ:CATB) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.31) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.02. The company had revenue of $0.25 million for the quarter. equities research analysts predict that Catabasis Pharmaceuticals will post -1.42 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Insider Buying and Selling by Quarter for Catabasis Pharmaceuticals (NASDAQ:CATB)

Receive News & Ratings for Catabasis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.